国产核药新适应症进军欧洲,加速全球市场拓展

动脉网
Sep 09, 2025

9月8日晚,远大医药公告其联营公司Sirtex Medical的SIR-Spheres®钇[90Y]微球注射液(易甘泰®)在欧洲获批新适应症CE认证,用于肝癌治疗,适用范围从原有的不可切除肝细胞癌和不可切除结直肠癌肝转移,扩展到不可切除肝内胆管癌、神经内分泌瘤引起的肝转移或其他肝转移等。近期,该注射液还获FDA批准新增HCC适应症,彰显了集团海外临床注册与商业化运营能力。海外临床数据将支持该产品在...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10